Ann: Alterity Phase 2 Presentation at AAN 2025, page-13

First 13 Last

Share
Profile

Follow
itsagas

14,651 Posts.

1583

16/04/25

09:37

Post #: 78707602
Share

Originally posted by shlok: ↑

I’m not negative, just objective .
im not taking a dig at you, but can you seriously interpret clinical data? Let me give you an example hopefully you understand… imagine an absolutely boring book with crap pictures in them right? Now the author keeps saying how awesome and excited they are with the book, but surely you can open the book and see for yourself the contradiction?
we have a great UMSARS score but not statistical significance for other end points.
now I ask you, if they are discussing with partners and if YOU were say Pfizer , would you want to partner on such data? Be objective in life. Zero emotions.
frankly I still feel they will Goto the FDA with a strong case to try and get AA but they will need to plan a phase 3 and the phase 3 will have to be a bulletproof design to capture more endpoints. Which probably means a few months wait till the study design is determined and they probably won’t end up going to FDA till probably August.
these are my opinions only. DYOR

Expand

hi Shlok
i was deeply concerned from your post re endpoints
So I asked ATH to clarify the results
Not having a dig at you..

ATH Price at posting: 0.8¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

RCE

Recce locks in $30M to boost commercialisation across ASEAN region

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

First 13 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.1¢		Change 0.000(0.00%)		Mkt cap ! $100.4M

Open	High	Low	Value	Volume
1.1¢	1.1¢	1.1¢	$88.06K	8.054M

Buyers (Bids)

No.	Vol.	Price($)
29	11330464	1.0¢

Sellers (Offers)

Price($)	Vol.	No.
1.1¢	1574126	5

View Market Depth

No.	Vol.	Price($)
29	11330464	0.010
27	26544228	0.009
15	28140963	0.008
13	24058106	0.007
14	8953518	0.006

Price($)	Vol.	No.
0.011	1574126	5
0.012	22384784	29
0.013	7780040	15
0.014	13313180	8
0.015	2059976	9

Last trade - 16.10pm 17/06/2025 (20 minute delay)

ATH (ASX) Chart

Ann: Alterity Phase 2 Presentation at AAN 2025, page-13

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Recce locks in $30M to boost commercialisation across ASEAN region

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Many are concerned about global falling birthrates. This diverse stock has solutions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Alterity Phase 2 Presentation at AAN 2025, page-13

Top Stories

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Recce locks in $30M to boost commercialisation across ASEAN region

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Many are concerned about global falling birthrates. This diverse stock has solutions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News